Preexposure Prophylaxis for the Prevention of HIV Infection in the United States – 2021 Update Clinical Practice Guideline
Page 98 of 108
48. Reece M, Herbenick D, Schick V, et al. Condom use rates in a national probability sample of males
and females ages 14 to 94 in the United States. JSex Med. 2010;7:266-276. doi:10.1111/j.1743-
6109.2010.02017.x
49. Koblin B, Chesney M, Coates T, et al. Effects of a behavioural intervention to reduce acquisition of
HIV infection among men who have sex with men: the EXPLORE randomised controlled study.
Lancet. 2004;364(9428):41-50. doi:10.1016/S0140-6736(04)16588-4
50. Peterman TA, Tian LH, Warner L, et al. Condom use in the year following a sexually transmitted
disease clinic visit. Int J STD AIDS. 2009;20(1):9-13. doi:10.1258/ijsa.2008.008177
51. Centers for Disease Control and Prevention. -HIV infection, risk, prevention, and testing behaviors
among persons who inject drugs — National HIV Behavioral Surveillance Injection Drug Use, 20
U.S. Cities, 2015. HIV Surveillance Special Report. 2018;18:1-38. Accessed 1 December 2019.
https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-hssr-nhbs-pwid-2015.pdf
52. Kral AH, Bluthenthal RN, Lorvick J, Gee L, et al. Sexual transmission of HIV-1 among injection drug
users in San Francisco, USA: risk-factor analysis. The Lancet. 2001;357(9266):1397-1401.
53. Strathdee SA, Stockman JK. Epidemiology of HIV among injecting and non-injecting drug users:
current trends and implications for interventions. Curr HIV/AIDS Rep. 2010;7(2):99-106.
54. Cardo DM, Culver DH, Ciesielski CA, et al. A case-control study of HIV seroconversion in health care
workers after percutaneous exposure. N Engl J Med. Nov 20 1997;337(21):1485-1490.
55. Benotsch EG, Zimmerman RS, Cathers L, et al. Non-medical use of prescription drugs and HIV risk
behaviour in transgender women in the Mid-Atlantic region of the United States. IntJournal STD
AIDS. 2016;27(9):776-782.
56. Wilson E, Rapues J, Jin H, et al. . The use and correlates of illicit silicone or “fillers” in a population‐
based sample of transwomen, San Francisco, 2013. Journal Sex Medicine. 2014;11(7):1717-1724.
57. Wilson EC, Jin H, Liu A, et al. . Knowledge, indications and willingness to take pre-exposure
prophylaxis among transwomen in San Francisco, 2013. PLoS One. 2015;10(6)
58. Smith DK, Pan Y, Rose CE, et al. A brief screening tool to assess the risk of contracting HIV infection
among active injection drug users. J Addict Med. 2015;9(3):226-32.
doi:10.1097/ADM.0000000000000123
59. Centers for Disease Control and Prevention. Integrated prevention services for HIV infection, viral
hepatitis, sexually transmitted diseases, and tuberculosis for persons who use drugs illicitly:
summary guidance from CDC and the U.S. Department of Health and Human Services. MMWR
Recomm Rep. Nov 9 2012;61(RR-5):1-40.
60. DiNenno EA. Recommendations for HIV screening of gay, bisexual, and other men who have sex
with men—United States, 2017. MMWR Morb Mortal Wkly Rep. 2017;66
61. US Preventive Services Task Force. Screening For HIV infection: Current recommendations, U.S.
Preventive Services Task Force. Updated 1 December 2019.
https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/hum
an-immunodeficiency-virus-hiv-infection-screening1
62. Mimiaga MJ, Reisner SL, Bland S, et al. Health system and personal barriers resulting in decreased
utilization of HIV and STD testing services among at-risk black men who have sex with men in
Massachusetts. AIDS Patient Care STDs. 2009;23(10):825-35. doi:10.1089/apc.2009.0086
63. Wejnert C, Prejean J, Hoots B, et al. Prevalence of missed opportunities for HIV testing among
persons unaware of their infection. JAMA. 2018;319(24):2555-2557.
64. Patel D, Johnson CH, Krueger A, et al. Trends in HIV testing among US adults, aged 18–64 years,
2011–2017. AIDS Behav. 2019:1-8.
65. Stekler JD, Ure G, O'Neal JD, et al. Performance of Determine Combo and other point-of-care HIV
tests among Seattle MSM. J Clin Virol. Mar 2016;76:8-13. doi:10.1016/j.jcv.2015.12.011